Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
The new site will feature a finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future, Novo Nordisk said.
“The facility will utilize advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” commented Henrik Wulff, executive vice president, Product Supply, Quality & IT of Novo Nordisk. “We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce.”
According to Novo Nordisk, construction work has started and is scheduled to be completed in 2027. The investment is expected to create 400 permanent jobs upon completion of the facilities.
The company stated that more than 4,000 new trees will be planted at the site and buildings will be equipped with solar panels to enhance on-site electricity generation. The landscape will be designed by reusing excess soil, wooden materials and other sustainable resources to create lakes, forests and community spaces open to the public.
Source: chemanager-online.com
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire obesity biotech Metsera. After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn offer.
French industrial group Anjac Health & Beauty has acquired food supplements supplier PharmaLinea and now comprises 17 complementary companies with R&D and production capacities in health, beauty, personal care, and food supplements.
The big pharma company will pay $221.50 per share in cash to buy Cidara, a US biotech that has developed a platform of drug-Fc conjugates (DFCs). The technology has allowed Cidara to build molecules with prolonged half-life whose efficacy does not require an immune response.
